Thereby, we demonstrated that scRNA-seq can capture genomic alterations accurately, including cancer- and patient-specific germline and somatic mutations in genes such as TP53, as well as gene fusions, including an IGF2BP2::TESPA1 fusion. This evidence concerns the gene TESPA1 and cancer.